Validation study to assess approximately 5,000 patients with participation from a multi-center group of leading U.S. investigators NEW YORK, Jan. 23, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced
Solutions to Improve Detection, Management and Treatment of Kidney Disease, Which Impacts More Than 850 Million Globally Mount Sinai to Collaborate for Launch of Initial Product, KidneyIntelX™, in 2019 NEW YORK, Nov. 15, 2018 /PRNewswire/ -- Renalytix AI plc (LSE AIM: RENX), a developer of
